ArticleJournal of immunology (Baltimore, Md. : 1950)2015
Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive.
Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- HLA-G regulation through trogocytosis: intercellular membrane transfer mechanisms and immune dysregulation in Systemic Lupus Erythematosus.Frontiers in cell and developmental biology · 2025Review
- The Biological Significance of Trogocytosis.Results and problems in cell differentiation · 2024Article
- The direct transfer approach for transcellular drug delivery.Drug delivery · 2023Review
- Outsmarting trogocytosis to boost CAR NK/T cell therapy.Molecular cancer · 2023Review
- NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells.Frontiers in immunology · 2023Article
- KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.Nature medicine · 2022Article
- Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.Journal for immunotherapy of cancer · 2022Article
- When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.Science advances · 2022Article
- Lymphocytes and Trogocytosis-Mediated Signaling.Cells · 2021Review
- Review
- A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics.eLife · 2020Article
- Unraveling exhaustion in adaptive and conventional NK cells.Journal of leukocyte biology · 2020Review
- Minimal PD-1 expression in mouse and human NK cells under diverse conditions.The Journal of clinical investigation · 2020Article
- AssessingBio-protocol · 2020Article
- Article
- HLA-G Neo-Expression on Tumors.Frontiers in immunology · 2020Review
- NK Cell Hyporesponsiveness: More Is Not Always Better.International journal of molecular sciences · 2019Review
- Trogocytosis-Mediated Intracellular Signaling in CD4Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Neutrophils kill the parasite Trichomonas vaginalis using trogocytosis.PLoS biology · 2018Article
- Leveraging natural killer cells for cancer immunotherapy.Immunotherapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Because NK cells secrete cytotoxic granules and cytokines that can destroy surrounding cells and help shape the subsequent immune response, they must be kept under tight control. Several mechanisms, at different levels, are in place to control NK cell function. In this study, we describe a novel mechanism regulating NK cell function in which NK cells acquire ligands for activating receptors from target cells by trogocytosis, rendering the NK cells hyporesponsive. In this model, murine NK cells acquire m157, the murine CMV-encoded ligand for the Ly49H-activating receptor, from target cells both in vitro and in vivo. Although acquisition of m157 requires cell-to-cell contact, it does not require the expression of the Ly49H receptor by the NK cell. Acquired m157 protein is expressed on the NK cell surface with a glycosylphosphatidylinisotol linkage and interacts with the Ly49H receptor expressed on the NK cell. This interaction results in blocking the Ly49H receptor that prevents the NK cells from recognizing m157-expressing targets and continuous engagement of the Ly49H-activating receptor, which results in the hyporesponsiveness of the Ly49H(+) NK cell to stimulation through other activating receptors. Thus, NK cell acquisition of a ligand for an activation receptor by trogocytosis renders them hyporesponsive. This mechanism, by which mature NK cell function can be altered, has important implications in regard to how NK cells respond to tumors in specific microenvironments as well as the use of expanded NK cells in treating various malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.